Last: | $20.515 |
---|---|
Change Percent: | 1.96% |
Open: | $20.18 |
Close: | $20.12 |
High: | $20.55 |
Low: | $20.12 |
Volume: | 307,529 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$20.515 | $20.18 | $20.12 | $20.55 | $20.12 | 307,529 | 07-03-2024 |
$20.12 | $20.16 | $20.12 | $20.38 | $20.05 | 912,802 | 07-02-2024 |
$20.31 | $20.82 | $20.31 | $21.01 | $20.17 | 1,483,376 | 07-01-2024 |
$20.7 | $20.76 | $20.7 | $21.03 | $20.515 | 2,030,415 | 06-28-2024 |
$20.59 | $20.59 | $20.59 | $20.71 | $20.3802 | 873,670 | 06-27-2024 |
$20.63 | $20.61 | $20.63 | $20.71 | $20.405 | 869,724 | 06-26-2024 |
$20.79 | $21.13 | $20.79 | $21.19 | $20.79 | 845,666 | 06-25-2024 |
$21.12 | $20.95 | $21.12 | $21.4399 | $20.9 | 1,427,125 | 06-24-2024 |
$20.84 | $20.61 | $20.84 | $20.93 | $20.31 | 3,375,414 | 06-21-2024 |
$20.45 | $20.22 | $20.45 | $20.54 | $20.15 | 1,123,162 | 06-20-2024 |
$20.35 | $20.3 | $20.35 | $20.44 | $20.21 | 1,572,467 | 06-19-2024 |
$20.35 | $20.3 | $20.35 | $20.44 | $20.21 | 1,572,467 | 06-18-2024 |
$20.35 | $20.31 | $20.35 | $20.54 | $19.88 | 1,418,747 | 06-17-2024 |
$20.4 | $20.27 | $20.4 | $20.455 | $19.82 | 1,402,136 | 06-14-2024 |
$20.51 | $20.77 | $20.51 | $20.84 | $20.465 | 1,223,911 | 06-13-2024 |
$20.84 | $20.81 | $20.84 | $21.15 | $20.62 | 1,833,272 | 06-12-2024 |
$20.26 | $20.58 | $20.26 | $20.66 | $20.165 | 3,843,072 | 06-11-2024 |
$20.71 | $20.56 | $20.71 | $20.815 | $20.36 | 1,107,549 | 06-10-2024 |
$20.75 | $20.53 | $20.75 | $20.81 | $20.32 | 900,307 | 06-07-2024 |
$20.67 | $20.81 | $20.67 | $21.015 | $20.55 | 952,157 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
2024-06-08 06:50:00 ET Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper. Three Motley Fool contributors have found stocks with mouthwatering dividends that you...
Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization applications (MAAs) for HLX14, an investigational Prolia ® and Xgeva ® (denosumab) biosimilar. Denosumab has been a...
2024-05-23 02:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...